Patents by Inventor Kiyoyuki Omoto

Kiyoyuki Omoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PPARg MODULATORS AND METHODS OF USE
    Publication number: 20230062861
    Abstract: Disclosed herein are novel compounds of Formula (1) and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing the same, and methods of using the same.
    Type: Application
    Filed: November 8, 2021
    Publication date: March 2, 2023
    Inventors: Sudeep PRAJAPATI, Hyelee LEE, Stephanos IOANNIDIS, Kiyoyuki OMOTO, Alan ROLFE, Xiang LIU, Megan SHEEHAN, Paul DRANSFIELD, Andrew COOK
  • Piperazine Compounds for Inhibiting CPS1
    Publication number: 20230026271
    Abstract: We provide compounds that may be useful as CPS1 inhibitors. These compounds may be useful, for example, in the treatment of cancer.
    Type: Application
    Filed: November 20, 2020
    Publication date: January 26, 2023
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Alan ROLFE, David BOLDUC, Nicholas LARSEN, Andrew S. COOK, Kiyoyuki OMOTO
  • 5-(Thiophen-2-YL)-1 H-Tetrazole Derivative as BCKDK Inhibitors Useful for Treating Various Diseases
    Publication number: 20220363673
    Abstract: Described herein are compounds of Formula I, wherein R1, R2, and R3 are defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.
    Type: Application
    Filed: June 24, 2020
    Publication date: November 17, 2022
    Applicant: Pfizer Inc.
    Inventors: Samit Kumar Bhattacharya, Christopher Ryan Butler, Kevin James Filipski, Bethany Lyn Kormos, Luis Angel Martinez-Alsina, Russell Alan Miller, Kiyoyuki Omoto, Brian Raymer, Matthew Richard Reese, Rachel Jane Roth Flach, Yuan Zhang
  • N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS
    Publication number: 20170305857
    Abstract: The present invention relates to compounds of Formula (I) described herein and their pharmaceutically acceptable salts, and their use in medicine, in particular as Trk antagonists.
    Type: Application
    Filed: December 8, 2014
    Publication date: October 26, 2017
    Applicant: Pfizer Limited
    Inventors: SARAH ELIZABETH SKERRATT, SHARANJEET KAUR BAGAL, NIGEL ALAN SWAIN, KIYOYUKI OMOTO, MARK DAVID ANDREWS
  • Tropomyosin-Related Kinase Inhibitors Containing Both A 1H-Pyrazole And A Pyrimidine Moiety
    Publication number: 20170197939
    Abstract: The present invention relates to compounds of Formula I and their prodrugs and pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as TrkA antagonists.
    Type: Application
    Filed: April 1, 2015
    Publication date: July 13, 2017
    Applicant: Pfizer Inc.
    Inventors: Sharanjeet Kaur Bagal, Jingrong Jean Cui, Samantha Elizabeth Greasley, Elizabeth Ann Lunney, Indrawan James McAlpine, Asako Nagata, Sacha Ninkovic, Kiyoyuki Omoto, Sarah Elizabeth Skerratt, Robert Ian Storer, Joseph Scott Warmus
  • N-Acylpyrrolidine Ether Tropomyosin-Related Kinase Inhibitors
    Publication number: 20160221989
    Abstract: The present invention relates to compounds of Formula I described herein and their pharmaceutically acceptable salts, and their use in medicine, in particular as Trk antagonists.
    Type: Application
    Filed: August 4, 2015
    Publication date: August 4, 2016
    Applicant: Pfizer Inc.
    Inventors: Sharanjeet Kaur Bagal, Kiyoyuki Omoto, Sarah Elizabeth Skerratt, Jingrong Jean Cui, Samantha Elizabeth Greasley, Indrawan James McAlpine, Asako Nagata, Sacha Ninkovic, Michelle Bich Tran-Dubé
  • Tropomyosin-related kinase inhibitors
    Patent number: 9328096
    Abstract: The present invention relates to compounds of Formula I and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as TrkA antagonists.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: May 3, 2016
    Assignee: Pfizer Inc.
    Inventors: Sharanjeet Kaur Bagal, Jingrong Jean Cui, Samantha Elizabeth Greasley, Elizabeth Ann Lunney, Indrawan James McAlpine, Asako Nagata, Sacha Ninkovic, Kiyoyuki Omoto, Sarah Elizabeth Skerratt, Robert Ian Storer, Joseph Scott Warmus
  • TROPOMYOSIN-RELATED KINASE INHIBITORS
    Publication number: 20150322043
    Abstract: The present invention relates to compounds of Formula I and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as TrkA antagonists.
    Type: Application
    Filed: May 6, 2015
    Publication date: November 12, 2015
    Inventors: SHARANJEET KAUR BAGAL, JINGRONG JEAN CUI, SAMANTHA ELIZABETH GREASLEY, ELIZABETH ANN LUNNEY, INDRAWAN JAMES MCALPINE, ASAKO NAGATA, SACHA NINKOVIC, KIYOYUKI OMOTO, SARAH ELIZABETH SKERRATT, ROBERT IAN STORER, JOSEPH SCOTT WARMUS
  • Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
    Patent number: 9163021
    Abstract: The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: October 20, 2015
    Assignee: Pfizer Limited
    Inventors: Mark David Andrews, Sharanjeet Kaur Bagal, David Graham Brown, Karl Richard Gibson, Wolfgang Klute, Inaki Morao, Kiyoyuki Omoto, Thomas Ryckmans, Yogesh Sabnis, Sarah Elizabeth Skerratt, Paul Anthony Stupple
  • Chemical Compounds
    Publication number: 20150259352
    Abstract: The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the GABAA receptor. They are useful in the treatment of a number of conditions, including pain.
    Type: Application
    Filed: May 29, 2015
    Publication date: September 17, 2015
    Inventors: Kiyoyuki Omoto, Robert McKenzie Owen, David Cameron Pryde, Christine Ann Louise Watson, Mifune Takeuchi
  • Pyrrolo[3,2-C]Pyridine Tropomyosin-Related Kinase Inhibitors
    Publication number: 20150246912
    Abstract: The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.
    Type: Application
    Filed: September 26, 2013
    Publication date: September 3, 2015
    Applicant: Pfizer Limited
    Inventors: Mark David Andrews, Sharanjeet Kaur Bagal, David Graham Brown, Karl Richard Gibson, Wolfgang Klute, Inaki Morao, Kiyoyuki Omoto, Thomas Ryckmans, Yogesh Sabnis, Sarah Elizabeth Skerratt, Paul Anthony Stupple
  • Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors
    Publication number: 20150218172
    Abstract: The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.
    Type: Application
    Filed: September 26, 2013
    Publication date: August 6, 2015
    Applicant: Pfizer Limited
    Inventors: Mark David Andrews, Sharanjeet Kaur Bagal, David Graham Brown, Karl Richard Gibson, Kiyoyuki Omoto, Thomas Ryckmans, Yogesh Sabnis, Sarah Elizabeth Skerratt, Paul Anthony Stupple
  • Chemical Compounds
    Publication number: 20150105396
    Abstract: The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the GABAA receptor. They are useful in the treatment of a number of conditions, including pain.
    Type: Application
    Filed: December 19, 2014
    Publication date: April 16, 2015
    Inventors: Kiyoyuki Omoto, Robert McKenzie Owen, David Cameron Pryde, Christine Ann Louise Watson, Mifune Takeuchi
  • Chemical compounds
    Patent number: 8952008
    Abstract: The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the GABAA receptor. They are useful in the treatment of a number of conditions, including pain.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: February 10, 2015
    Assignee: Pfizer Limited
    Inventors: Kiyoyuki Omoto, Robert McKenzie Owen, David Cameron Pryde, Christine Ann Louise Watson, Mifune Takeuchi
  • PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS
    Publication number: 20140364415
    Abstract: The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.
    Type: Application
    Filed: August 26, 2014
    Publication date: December 11, 2014
    Applicant: PFIZER LIMITED
    Inventors: Mark David Andrews, Sharanjeet Kaur Bagal, Karl Richard Gibson, Kiyoyuki Omoto, Thomas Ryckmans, Sarah Elizabeth Skerratt, Paul Anthony Stupple
  • Pyrrolo[2,3-d]pyrimidine tropomysin-related kinase inhibitors
    Patent number: 8846698
    Abstract: The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: September 30, 2014
    Assignee: Pfizer Limited
    Inventors: Mark David Andrews, Sharanjeet Kaur Bagal, Karl Richard Gibson, Kiyoyuki Omoto, Thomas Ryckmans, Sarah Elizabeth Skerratt, Paul Anthony Stupple
  • Chemical Compounds
    Publication number: 20140171435
    Abstract: The present invention relates to imidazopyridazine derivatives. More particularly, it relates to 4-(biphenyl-3-yl)-7H-imidazo[4,5-c]pyridazine derivatives of formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are as defined in the description. The imidazopyridazine derivatives of the present invention modulate the activity of the GABAA receptor. They are useful in the treatment of a number of conditions, including pain.
    Type: Application
    Filed: December 12, 2013
    Publication date: June 19, 2014
    Applicant: Pfizer Limited
    Inventors: Kiyoyuki Omoto, Robert McKenzie Owen, David Cameron Pryde, Christine Ann Louise Watson, Mifune Takeuchi
  • PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS
    Publication number: 20120258950
    Abstract: The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.
    Type: Application
    Filed: April 4, 2012
    Publication date: October 11, 2012
    Applicant: PFIZER LIMITED
    Inventors: Mark David Andrews, Sharanjeet Kaur Bagal, Karl Richard Gibson, Kiyoyuki Omoto, Thomas Ryckmans, Sarah Elizabeth Skerratt, Paul Anthony Stupple